This introductory textbook of pharmacoeconomics is ideal for all those working in, aspiring to work in or interested in the pharmaceutical industry. It assumes no prior knowledge of this subject but is written at a level appropriate, for example, for those studying for a postgraduate degree or diploma in pharmaceutical medicine and who already have a first degree in science or medicine.
- Emphasizes how pharmacoeconomics can be of assistance in "real world" decision making.
- Covers the development of insuring, financing and delivery of health care in the developed world and the increasing role of governments.
- Explains the trend towards the critical scrutiny of health service activity.
- All topics explained assuming no specialist knowledge.
|Author Informaiton||By Tom Walley, MD, FRCP(London), FRCPI, Professor of Clinical Pharmacology, University of Liverpool; Honorary Consultant Physician, Royal Liverpool University Hospital, Liverpool, UK; Alan Haycox, MD, Department of Pharmacology and Therapeutics, University of Liverpool Medical School, Liverpool, UK; and Angela Boland, MD, Department of Pharmacology and Therapeutics, University of Liverpool Medical School, Liverpool, UK|
|Published Reviews||"This book provides a solid yet concise introduction to the field of health economics with an emphasis on its application to medicines. The aim of the book is to introduce the non-specialist reader to the theory as well as to the practice of health economics...recommended to anyone wishing to acquire a better, yet critical, understanding of this rapidly emerging field." Health Economist, University of York, The Pharmaceutical Journal, April 2004
far as Pharmacoeconomics books go' this one is the nearest thing you'll get to 'un-put-down-able'." Medical Advisor & Pharmaceutical Physician, Pharmaceutical Physician, May 2004
|Table of Content||Basics of economics, health economics and pharmacoeconomics. The policy context for pharmacoeconomics. The economics of health care and health care systems. Pharmacoeconomics: an industry perspective. Disease management and programme budgeting and marginal analysis. Cost of illness studies. Approach to pharmacoeconomic analysis. Pharmacoeconomics and clinical trials. Modeling in health economics. Quality assurance in pharmacoeconomic analyses. Future directions.|